- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Single-fraction stereotactic body radiotherapy promising for local prostate cancer recurrence
Researchers from Germany found that even in intensively pretreated prostate cancer patients single-fraction, PSMA-PET- and mpMRI-guided focal stereotactic body radiotherapy was found to be safe, efficient, and timesaving. The study results were published in the journal BJU International.
Prostate cancer (PCa) is the most frequent malignant tumor in adult men. There are various combinations of therapies like radical prostatectomy, external beam radiotherapy, or a combination of both. New therapeutic advances have developed with the use of stereotactic body radiotherapy (SBRT). But to date evidence has been limited to the use of fractionated stereotactic body radiotherapy (SBRT) with not much data on single-fraction SBRT in conjunction with prostate-specific membrane antigen positron emission tomography (PSMA-PET) and multiparametric magnetic resonance imaging (mpMRI) guidance. Hence researchers from Germany conducted a study to analyze the efficacy and safety of focal PSMA-PET and mpMRI-guided single-fraction stereotactic body radiotherapy (SBRT) for the treatment of PCa local recurrences.
Patients with PSMA-PET-positive PCa local recurrences treated with single-fraction SBRT between 2016 and 2020 were included. Subsequent recurrences or metastatic spread were identified based on increasing prostate-specific antigen (PSA) levels and PSMA-PET imaging was used for the evaluation.
Results:
- A total of 64 patients were identified.
- Patients received various treatments before SBRT 31 patients were treated with radical prostatectomy [RP], 18 with external beam radiotherapy [EBRT] with RP, five with EBRT, and the remaining 10 were given other combinations.
- The median follow-up was 21.6 months.
- The median PSA level before SBRT was 1.47 ng/mL.
- A single-fraction treatment with a median prescription dose and isodose line of 21 Gy and 65%, were given to all patients respectively.
- At the time of SBRT, six patients (9%) received androgen deprivation therapy (ADT).
- PSA levels decreased after SBRT (P = 0.03) and three local recurrences were detected during the follow-up.
- The progression-free survival after 1-, 2-, and 3 years was 85.3%, 65.9%, and 51.2%, respectively.
- Six patients (9%) started ADT after SBRT due to disease progression.
- The rates of newly started ADT after 1-, 2-, and 3 years were 1.8%, 7.3%, and 22.7%, respectively. Grade 1 or 2 toxicities occurred in six patients (9%); no high-grade toxicity was observed.
Thus, this first analysis of single-fraction, PSMA-PET- and mpMRI-guided focal SBRT has shown promising results. The use of ADT could be delayed with recurrence-directed treatments and could avoid prostate bed irradiation in selected patients.
Take-home points:
- Stereotactic body radiotherapy (SBRT) is an emerging technology that has become increasingly used to treat localized prostate cancer. This study was the first to evaluate prostate-specific membrane antigen PET– or multiparametric MRI–guided single-fraction SBRT in patients with prostate cancer recurrence. There were 64 patients identified, with the majority having previously undergone radical prostatectomy. There were significant reductions in prostate-specific antigen (PSA) levels after SBRT. The progression-free survival rate at 3 years was 51.2%. There were no instances of high-grade toxicity.
- This study of single-fraction SBRT for local prostate cancer recurrence found that the treatment was well-tolerated and resulted in a significant reduction in PSA levels that appeared durable.
Further reading: Ehret F, Hofmann T, Fürweger C, et al. Single-fraction prostate-specific membrane antigen positron emission tomography- and multiparametric magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer local recurrences [published online ahead of print, 2022 Sep 17]. BJU Int. 2022;10.1111/bju.15894. doi:10.1111/bju.15894
BDS, MDS
Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751